International Journal of Medicine and Data

Objective To explore the application value of combined detection of blood biochemical and immunological indexes in the diagnosis of lung cancer. Methods 51 patients with lung cancer who were admitted from October 2024 to September 2025 were selected as the observation group, and 51 healthy individuals undergoing physical examinations during the same period were selected as the control group. Both groups underwent chemiluminescence immunoassay monitoring, and the diagnostic efficacy of single indicators and combined indicators was analyzed through ROC curve. Results The levels of CEA, CYFRA21-1, NSE, SCC, and ProGRP in the observation group were significantly higher than those in the control group (P<0.05); the CEA level was the highest in patients with adenocarcinoma; the CYFRA21-1 level was the highest in patients with squamous cell carcinoma; the SCC level was the highest in patients with squamous cell carcinoma; the NSE level was the highest in patients with small cell lung cancer; the ProGRP level was the highest in patients with small cell lung cancer (P<0.05); the AUC (0.927), sensitivity (89.25%), and specificity (86.74%) of combined detection were all higher than those of single indicators (P<0.05). Conclusion Combined detection of blood biochemical and immunological indexes can significantly improve the accuracy of lung cancer diagnosis and can be used as an important reference indicator for early pathological diagnosis.

Blood biochemical and immunological indexes; Testing; Lung cancer; Diagnostic efficacy